FdaApplication
NDA 213793
Identifiers
- fda_app_no: NDA213793
Properties
| Property | Value |
|---|---|
| applicant_name | RHYTHM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2020-11-25 |
Revenue by product
IMCIVREE
| Period | Revenue |
|---|---|
| Q2 2026 | $71.3M |
| Q1 2026 | $60.1M |
| Q4 2025 | $57.3M |
| Q3 2025 | $51.3M |
| Q1 2025 | $37.7M |
| Q3 2024 | $33.3M† |
| Q2 2024 | $29.1M† |
| Q1 2024 | $26.0M† |
| Q3 2023 | $22.5M† |
| Q2 2023 | $19.2M† |
| Q1 2023 | $11.5M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| IMCIVREE | SETMELANOTIDE ACETATE | EQ 10MG BASE/ML (EQ 10MG BASE/ML) | SOLUTION;SUBCUTANEOUS |
1 product